01
Collaborative Development
Aditri Pharma Sciences Private Limited, an envisioned pharmaceutical company is engaged in the collaborative development and manufacturing of niche pharmaceutical products for the generic industry.
Company Profile
Collaborative development and manufacturing for the generic industry.
Aditri Pharma Sciences Private Limited, an envisioned pharmaceutical company is engaged in the collaborative development and manufacturing of niche pharmaceutical products for the generic industry.
Aditri Pharma Sciences is committed to the highest standards in health care. We strive to satisfy unmet needs in dosage forms to increase compliance and constantly work on bringing down the cost of PPPY without compromising quality, efficacy, or safety.
Operating Model
Flexible capacity, Regulated execution.
Aditri Pharma Sciences follows an asset-free model. We collaborate with SRA-approved manufacturing partners rather than having our own manufacturing sites.
Source regulatory-compliant products
Support documentation like API DMFs, dossiers, and bioequivalence studies (BE)
Ensure quality and global regulatory alignment
Faster turnaround without infrastructure delays
Access to diverse product portfolios across therapeutic segments
Scalable solutions tailored to regional regulatory environments
By coordinating pharmaceutical solutions through an established network, Aditri helps clients streamline development while maintaining control over regulatory compliance and quality.
Indian Expertise with Global Outlook
Science, capacity
and regulated execution.
Aditri Pharma Sciences identifies potential partners for strategic tie-up for finished dosages in HIV/AIDS, Tuberculosis, Hepatitis B, and generics.
02
Asset-Free Model
Aditri Pharma Sciences follows an asset-free model. We collaborate with SRA-approved manufacturing partners rather than having our own manufacturing sites.
03
WHO-PQ Audit
Aditri has been successfully audited by WHO-PQ in July 2026.
04
Market Authorization
Aditri holds the Market Authorization (MA) for Finished Dosages and select APIs.
05
Strategic Partnerships
Aditri Pharma Sciences identifies potential partners for strategic tie-up for finished dosages in HIV/AIDS, Tuberculosis, Hepatitis B, and generics. Our partners include Global Fund, Access Markets, and UN-based agencies.
Therapeutic Areas
HIV/AIDS, Tuberculosis, Hepatitis B, and generics at the center of the portfolio.
Aditri Pharma Sciences identifies potential partners for strategic tie-up for finished dosages in HIV/AIDS, Tuberculosis, Hepatitis B, and generics.
HIV/AIDS
Anti-Retroviral (ARV)
First and second-line treatment for HIV/AIDS in adults and pediatrics. PEPFAR-eligible, WHO-prequalified APIs.
TB Control
Tuberculosis (TB)
Specialized APIs for high-risk TB patients including drug-resistant strains. Meeting global WHO standards.
Liver Health
Hepatitis
Chronic and acute Hepatitis B (HBV) and C (HCV) treatment APIs for global generic markets.
Generics
Generic API
Niche pharmaceutical actives for the global generic industry. USFDA and SRA-market ready.
Aditri has been successfully audited by WHO-PQ in July 2026.Aditri holds the Market Authorization (MA) for Finished Dosages and select APIs.Aditri has been successfully audited by WHO-PQ in July 2026.Aditri holds the Market Authorization (MA) for Finished Dosages and select APIs.
✦ API - WHO-PQ✦ Dosages - USFDA✦ WHO-Geneva✦ MHRA✦ SAPHRA✦ EU GMP✦ BA/BE - USFDA✦ MHRA/EU GMP✦ API - WHO-PQ✦ Dosages - USFDA✦ WHO-Geneva✦ MHRA✦ SAPHRA✦ EU GMP✦ BA/BE - USFDA✦ MHRA/EU GMP
